Background: BBR 2778 is a novel aza-anthracenedione showing no cardiotoxicity and superior activity compared to doxorubicin and mitoxantrone in animal models. Objectives of this phase I study included the determination of the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), clinical pharmacokinetics (PK), and antitumor activity. Patients with relapsed or refractory, advanced non-Hodgkin's lymphoma were included.
Introduction
Anthracyclines belong to the most effective cytotoxic drugs and are widely being used in the treatment of solid tumors and hematological malignancies [1] . However, their clinical use is limited due to acute and cumulative cardiotoxicity [2, 3] . The anthracycline derivate mitoxantrone (Mitox), an anthracenedione, has an improved toxicity profile compared to the anthracyclines, but is also known to induce cardiomyopathy. This is probably caused by the 5,8-dihydroxy substitution pattern [4, 5] . Therefore, anthracenediones devoid of these hydroxy groups were evaluated for possible clinical use. Nitrogen atoms were introduced into the anthrachinone chromophore in order to create additional hydrogen bonding and basic sites, thereby maintaining the planar structure of the parent compound. These modifications were performed to modulate the affinity for DNA and to affect the interaction with topoisomerase II. It was found that only mono-aza derivates bearing the nitrogen in position 2 had antitumor activity. Further screening identified BBR 2778 (6,9- bis {(2-amino)ethyl]amino}-benzo[g]isoquinoline-5,10 -dione dimaleate, Figure 1 ).
The mechanism of action of BBR 2778 is similar to Mitox, including intercalation with DNA, strand breaks, and interaction with topoisomerase II [6, 7] . In vitro studies using a panel of 60 tumor cell lines showed a wide range of cytotoxic potency which was most pronounced in leukemias and non small cell lung cancer. BBR 2778 was approximately ten times less potent compared with Mitox in vitro. The compound showed complete cross-resistance with doxorubicin in MDR over-expressing cell lines such as LoVo/DX. In addition, the drug was partially cross-resistant with mitox- Figure antrone in HT29/Mitox, a cell line which shows specific resistance to mitoxantrone probably unrelated to gpl70 orMDR.
Importantly, BBR 2778 gave superior cytotoxic activity in P388-and L1210 murine leukemias compared to Mitox and Dx. The compound induced lasting complete remissions over a wide range of dose in ascitic L1210 murine leukemia and disseminated YC-8 lymphoma. In contrast to Mitox and Dx, BBR 2778 had a broader therapeutic range showing activity at one third of the MTD. In addition, when combined with cisplatinum BBR 2778 showed synergistic effects in a disseminated murine leukemia model, while Mitox showed no synergy. In mice, BBR 2778 induced reversible myelosuppression, atrophy of the testes, and minimal renal toxicity (acute tubular degeneration). The latter finding occurred only in rodents, not in dogs. The autopsy of treated animals revealed a blue pigmentation of all organs due to the rapid distribution of the dark-blue BBR 2778 solution. Sudden death associated with the administration of BBR 2778 was observed in rodents treated with a bolus injection, was dose and concentration dependent and occurred only at very high doses. Prolonging the infusion time completely abrogated the sudden death phenomenon. This effect was probably related to marked hyperkalemia derived from muscle fibers damaged by high blood concentration of the compound. In contrast to Mitox, mice treated with BBR 2778 at equieffective doses showed no signs of acute or delayed cardiotoxicity [8] . On the basis of these data, clinical trials in patients with solid tumors and malignant lymphoma were initiated.
We report the first clinical results with BBR 2778 in a phase I dose escalation study showing that this new compound induces a remarkable number of remissions in intensively pretreated patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).
Patients and methods

Patients
Eligible patients had measurable and active advanced or refractory NHL not amendable for conventional chemotherapy including the following entities according to the REAL classification, chronic lymphocytic leukemia (CLL) pretreated with chlorambucil and fludarabine, mantle-cell lymphoma in first relapse, follicular NHL in second or subsequent relapse and aggressive NHL of any histology in second or subsequent relapse. Pretreatment with anthracychnes and radiotherapy was allowed. Prior chemotherapy had to be completed four weeks before study drug administration. Prior radiotherapy had to be ceased six weeks before study entry. Other inclusion criteria were World Health Organization (WHO) performance status of 2 or less, age between 18 and 75 years, white blood cell count greater than 2.5 x 10 9 /l. platelet count greater than 80 x 10 9 /l, hemoglobin level greater than 10 g/dl, bilimbin levels less than two times and liver enzyme level less than three times above the upper normal limit, creatinine clearance greater than 65 ml/min, normal cardiac function as measured by echocardiography with a baseline left ventricular ejection fraction (LVEF) greater than 50%. no history of myocardial infarction or current history of angina, no cardiac arrhythmia and no other major medical problems. No new administration of a corticosteroid regimen during the study was allowed. The protocol was approved by the institutional ethics committee and patients had to give written informed consent as to the investigational nature of the treatment
Study design
This clinical trial was an open-label, non-randomized, phase I doseescalation study. Primary objective was to determine the maximum tolerated dose (MTD) of BBR 2778 in humans when administered by intravenous infusion over one hour weekly on days 1, 8 and 15. Secondary objectives included the pharmacokinetics, the dose limiting toxicity (DLT), and any antitumor activity. Patients received at least one course of treatment consisting of three infusions. Additional courses could be added according to the individual investigator's judgement in responding patients. Dose limiting toxicity was defined as any WHO grade 4 toxicity excluding nausea and vomiting. In addition, hematological toxicity WHO grade 3 lasting longer than one week, and hepato, cardiac, pulmonary or renal toxicity WHO grade 3 were defined as dose-limiting.
Dose escalation
BBR 2778 was escalated using the modified Fibonacci dose escalation scheme starting at a dose of 5 mg/m 2 /d, which corresponded to 1 of 10 of the DLT in the mouse-model. Escalation was performed as follows: 100%, 67%, 50%. 40%, and each following level 50%. At least three patients on each dose level were treated. Another three patients had to be included on the same dose level if a DLT occurred MTD was defined as the dose level below the dose limited by toxicity. This dose was defined by the occurrence of a DLT in at least two of three or six patients, respectively. Patients were monitored weekly including complete blood cell count, biochemistry, urine status, performance status and toxicity assessment according to WHO criteria On day 28 of each course, baseline evaluations were repeated including electrocardiography, chest X-ray, echocardiography, lung function test, creatinine clearance and assessment of tumor response.
Drug administration
BBR 2778 was supplied by Boehringer Mannheim Italy (Monza. Italy, now Novuspharma) in vials containing 10 mg and 50 mg of the drug, respectively, formulated as sterile dark-blue lyophilized powder. The drug was diluted in 500 ml normal saline immediately prior to administration by one hour infusion. Antiemetic prophylaxis was only applied after nausea had been observed with the previous drug application
Pharmacokinetics
On the first day of BBR 2778 administration, blood samples were drawn in heparinized tubes at the following time points, pre-injection. 5. 30. 60. and 75 minutes, as well as 2. 2.5, 3,4.6. 8. 12. 24. and 48 hours after injection. Starting with the eleventh patient, a further sample was added at 55 minutes after injection because the pharmacokinetic analysis of the first patients had shown a rapid plasma clearance Plasma was separated from blood cells by spinning at 1.200 g for 10 minutes and subsequently stored at -20 °C until analysis Urine was collected and samples of 100 ml stored at -20 °C degree until analysis at the following time points: from -12 hours pre-injection to injection time 0. from 0 to 4, 4 to 8, 8 to 12, and 12 to 24 hours after injection. The samples were analyzed using a validated high-pressure liquid chromatography (HPLQ with a limit of quantification (LOQ) of 2 ng/ml (3.6 nM). The individual plasma concentration-time profiles of BBR 2778 were analyzed after the first administration of each treatment cycle by a model independent approach, using the pharmacokinetic software Siphar version 4.0 (Simed, Creteil, France). Number of prior  chemotherapies   4  7  2  2  2  2  4  1  2  3  4  2  3  2  2  3  4  3  2  1  2  2  2  2  4  2 Abbreviations, fl -follicular lymphoma; tfl -transformed follicular lymphoma. dlcl -diffuse large-cell lymphoma; mcl -mantle-cell lymphoma, ell -chronic lymphocytic leukemia; pp -primary progressive.
Assessment of response
Complete remission (CR) was defined as the absence of any clinical or radiological evidence of active disease over a period of at least four weeks. Partial remission (PR) was defined as 50% or more decrease in the product of the two largest perpendicular diameters of all measurable lesions, as determined by two consecutive observations not less than four weeks apart. Less than 50% decrease or less than 25% increase in total tumor mass, again persisting for at least four weeks, were defined as no change (NC). Progressive disease was defined as the appearance of any new lesions or an increase of more than 25% in tumor size. Responses for the patients with CLL were assessed using the American National Cancer Institute Sponsored Working Group recommendation [9] Results
Patient characteristics
A total of 26 patients treated on 7 different dose levels were included and evaluated (Table 1 ). The median age was 59.5 years ranging from 33 to 74 years, 5 of 26 patients had primary progressive disease, 8 were treated in their second, 9 in their third, 3 in their fourth and 1 patient in her fifth relapse. A median of 2 prior chemotherapies had been administered, ranging from 1 to 7. Seventeen of twenty-six patients had stage IV; eleven of wenty-six had B-symptoms on study entry. Two patients were treated with three courses of BBR 2778, five patients received two courses (4/5: 6 applications, 1/5: 5 applications), sixteen patients one course, and in three patients therapy had to be stopped before the first course could be completed due to rapidly progressive disease.
Toxicity Myelosuppression
As shown in Table 4 , BBR 2778 was very well tolerated in the range from 5 to 56 mg/m 2 /d (dose levels 1-6), with no hematological toxicity in the three patients treated at 56 mg/m 2 /d (sixth dose level). DLT occurred with the seventh dose level (84 mg/m 2 /d) in three of six patients who developed neutropenia WHO grade 4. The remaining three patients on this dose level had neutropenia WHO grade 3 lasting longer than one week. There was no episode of febrile neutropenia. Also on the seventh dose level, thrombopenia WHO grade 4 and anemia WHO grade 3 occurred in one patient. Thus, DLT of BBR 2778 is neutropenia.
Other toxicities
On the seventh dose level, one patient suffered from diarrhea WHO grade 4. Although clostridium difficile toxin was found in this patient's stool, relation to the study drug cannot be excluded. With the first application of BBR 2778, nausea was seen in all six patients treated on the seventh dose level (WHO grade 1, 2 of 6; grade 2, 3 of 6; grade 3, 1 of 6) and vomiting in three (WHO grade 1, 1 of 6; grade 2, 1 of 6; grade 4, 1 of 6). On dose levels 1-6, nausea WHO grade 1 was seen in two patients, grade 2 in two patients, and grade 3 in one patient. Vomiting WHO grade 1 occurred in one patient, and grade 2 in another. In all of these patients, nausea and vomiting could be prevented by adding 8 mg ondansetron prior to the application of BBR 2778 in the following courses. Alopecia WHO grade 2 occurred in two patients with the seventh dose level and WHO grade 1 in one patient treated with the fourth dose level. Two infectious episodes requiring prolonged hospitalization occurred (one Pneumocystis carinii pneumonia in a patient treated with high dose corticosteroids for two months without prophylactic medication and one Herpes zoster infection in a patient known for recurrent Herpes zoster infections) that were not related to the study drug. Blue discoloring of the skin was observed in one patient after administration of the maximum cumulative dose of BBR 2778 given in one patient, corresponding to 1376.1 mg ( Table 2 ). This discoloring was completely reversible after three days. Temporary blue to green discoloration of the urine was seen in all 26 patients. No other toxicity was observed, especially neither nephrotoxicity nor cardiotoxicity.
Pharmacokinetics
Twenty-four of twenty-six patients were available for the analysis of BBR 2778 concentrations in plasma and urine (Figure 2 for plasma concentration curves). Overall, the distribution and elimination pattern does not seem to be affected by the dose increase from 5 mg/m 2 to 84 mg/m 2 ( Table 3 ). The maximum concentration (C max ) and the area under the curve (AUC) increased proportionally with the administered dose (Table 3, Figure 3 ). Plasma clearance (CL), half-life (t'/2, z), apparent volume of distribution at steady state (Vss), and dose adjusted AUC (AUC/D) remained constant, suggesting a linear kinetic for BBR 2778 in the tested dose range. Plasma clearance of BBR 2778 was high ranging from 0.65 to 1.74 l/h/kg. The drug showed a large volume of distribution at steady state (13.5-17.5 I/kg) and a long elimination half-life (14.7-31.9 h). The slow decline of the plasma concentrations results in a VA, z value of about 20 hours. This is, however, not in contrast with the clearance observed indicating an efficient drug elimination. The amount of BBR 2778 in the plasma that can be cleared by the liver and kidneys is low compared to the amount in the body. Thus, the overall drug elimination is prolonged resulting in a high elimination half-life. Only 3.9%-7.8% of the administered dose were detected in the 0-24-hour urine as unmodified drug.
Tumor response
As shown in Table 2 , there was a total of 5 of 26 responses including 3 CR and 2 PR. All complete remis- sions were observed on the seventh dose level. One patient with diffuse large-cell lymphoma in second relapse stage IIIA presenting with a cervical bulk tumor (7 cm in diameter) and enlarged abdominal lymph nodes, attained a complete remission (CR) after one course of BBR 2778. Therapy was not continued because of diarrhea WHO grade 4 and severe myelosuppression. CR lasted for eight months. A second patient with a primary refractory follicular NHL stage IVB with bone marrow involvement and pleural effusions achieved a CR after 2 cycles, lasting for 12+ months. A third patient treated for the second relapse of an aggressive B-NHL stage IVA with enlargement of mediastinal and abdominal lymph nodes and bone marrow infiltration, received a total of three courses and the remission has been lasting for 14+ months at the time this report is written.
Two partial responses were documented. One occurred in a patient with transformed aggressive NHL stage IIIA in third relapse, with enlargement of the spleen, axillary and inguinal lymph nodes, who was treated with the first dose level. Tumor response was documented after the 1st course BBR 2778 and therapy was stopped after the second cycle. Progressive disease occurred two months after the end of the second course. Another PR occurred with the sixth dose level in a patient who was treated for a mantle-cell lymphoma in third relapse, stage IVB, with enlargement of the spleen, abdominal lymph nodes and bone marrow infiltration. In this patient, a clear reduction (> 50%) of the abdominal tumor masses was seen, but therapy was not continued due to a severe cutaneous Herpes zoster infection.
Response to BBR 2778 with the second dose level was seen in a patient with a pleomorphic T-cell NHL stage IVB in third relapse, with infiltration of the bone marrow and of the iliopsoae and iliac muscles on the right and left side. After the first course of BBR 2778, a marked reduction (> 50%) of the muscle infiltration was observed accompanied by an impressing clinical improvement. Despite this response, skin lesions occurred seven weeks after the start of BBR 2778 therapy ( Table 2) and PD was documented. The response may be due to accumulation of the compound in the skeletal muscle. In the animal model, the highest percentage of the administered dose was found in the skeletal muscle (25.2% at 5 min in mice and 31.5% at 1 hour in rats). In the remaining patients, progressive disease was documented in 9 patients, and no change in 11.
Discussion
The following major findings emerge from this phase I study: 1) For phase II studies, the recommended weekly dose of the new aza-anthracenedione BBR 2778 is 84 mg/m 2 or 252 mg/m 2 for a complete course, i.e., day 1, 8, 15 application. The DLT on this dose level is myelosuppression, in particular neutropenia, whereas other main toxicities are either manageable (nausea) or of low clinical relevance (alopecia, temporary bluish skin discoloration). 2) The major pharmacokinetic features of BBR 2778 are similar to those of the parent compound Mitox including a high plasma clearance, a large volume of distribution and a long elimination half life. 3) There is clear evidence of cytotoxic activity in patients with heavily pretreated and advanced NHL.
In general, BBR 2778 was very well tolerated. The DLT manifested as neutropenia WHO grade 4 observed in three of six patients with the seventh dose level (84 mg/m 2 /d). There was no episode of febrile neutropenia. The lowest neutrophil count was observed on day 14 or 21, with the exception of one patient who had the nadir on day 28. Available data indicate that complete recovery occurs about one week later. In one patient only, who had a proven very poor bone marrow capacity requiring dose reduction in prior chemotherapies, thrombopenia WHO grade 4 and anemia WHO grade 3 occurred on the seventh dose level. Overall, the hematological toxicity of this second generation anthracenedione has to be interpreted with care, since the patients in this phase I study were heavily pretreated including a median of 2 prior chemotherapies and additional radiotherapy in 15 of 26 patients. Thus, most of the patients had a markedly reduced hematopoietic capacity possibly leading to an overestimation of the myelosuppressive effects of BBR 2778. Including the sixth dose level (56 mg/m 2 /w) neither severe hematological nor other organ toxicity was seen apart from nausea and vomiting. The only other severe adverse event possibly related to BBR 2778 was colitis with diarrhea WHO grade 4 occurring in one patient on the seventh dose level. Diarrhea was not seen in any other patient. Importantly, no clinical signs of cardiotoxicity were observed. This finding is consistent with the preclinical results in the animal model. However, more clinical application of BBR 2778 is required to establish more precisely the cardiotoxic potential of this new compound. Though by definition the MTD of BBR 2778 in this trial is 56 mg/m 2 /w, we recommend 84 mg/m 2 /w for further phase II studies to avoid uneffective treatment. This dose is safe in less pretreated patients, as could be seen in a very similar phase I study of BBR 2778. In this trial, patients with solid tumors were treated and the MTD was reached at 112 mg/m 2 /w using the same schedule [10] .
The pharmacokinetic characteristics of BBR 2778 found in this study are similar to those of Mitox and the anthracyclines [11] . This includes a large volume of distribution of the drug at steady state and a rapid plasma clearance. Compared to Mitox, BBR 2778 is cleared more rapidly from the plasma compartment [12] [13] [14] . At doses exceeding 16.5 mg/irr, the renal clearance of BBR 2778 approaches the glomerular filtration rate in humans (103 ml/h/kg). This means that the compound may be excreted by simple filtration through the kidneys. Binding to plasma proteins may not affect the excretion rate. In accordance with these findings, previous studies have shown that BBR 2778 is only weakly bound to plasma proteins [15] . Based on the estimates for the distribution volume, accumulation of BBR 2778 in tissues seems to be smaller when compared with Mitox. As a consequence of the higher clearance and smaller distribution, the half-life of BBR 2778 is shorter compared to Mitox (37.4-215 hours). Therefore, accumulation of BBR 2778 is unlikely with the schedule we used in this trial. Since the renal elimination of BBR 2778 (ranging from 3.9% to 7.8%) is low, it may be eliminated mainly by hepatic metabolism and biliary excretion. This would be in accordance with preclinical studies showing a feacal excretion rate of about 40% of the administered dose in rodents [16, 17] . Further studies should also include evaluation of this elimination route in men.
In addition to its good tolerability, BBR 2778 showed antitumor activity in patients with advanced heavily pretreated or refractory NHL, who are known to have a particularly poor prognosis [18] . We observed a total of five responses (3 CR and 2 PR). Importantly, four of five remissions were documented in patients pretreated with anthracyclines. One of three CRs is ongoing at 23+ months at the time this report is written. Although our data suggest a correlation between the dose of BBR 2778 and response with a maximum activity on the highest dose, responses on lower dose levels were observed. This might be related to the preclinical data showing effectivity of BBR 2778 over a wide range of dosage (starting at 1 /3 of MTD) in contrast to Mitox and Dx. In one patient with muscle infiltration of aT-NHL response to BBR 2778 and corresponding clinical improvement was seen. This may be due to accumulation of the compound in the skeletal muscle, as it was seen in the animal model (25.2% at 5 min in mice and 31.5% at 1 hour in rats).
In summary, the new aza-anthracenedione BBR 2778 is well tolerated with neutropenia being the main toxicity. The drug seems to be active in heavily pretreated patients with advanced NHL. These features and the lack of cardiotoxicity observed so far makes this new compound very interesting for further evaluations in clinical phase II studies.
